What is MOgene?
Established in 2004, MOgene operates as a specialized provider of genomic solutions, catering to a diverse clientele that spans the pharmaceutical, biotechnology, and government sectors. The company distinguishes itself through a consultative service model that integrates biopharma genomic services, agritech innovation, and advanced microbiome analysis. By leveraging sophisticated bioinformatics, MOgene facilitates complex research projects, ensuring that both small-scale academic inquiries and large-scale industrial initiatives receive high-fidelity data outputs. Their market position is defined by a long-standing reputation for technical precision and a deep-rooted expertise in translating genomic data into actionable insights for medical and agricultural advancement.
How much funding has MOgene raised?
MOgene has raised a total of $373K across 2 funding rounds:
Debt
$150K
Debt
$223K
Debt (2020): $150K with participation from PPP
Debt (2021): $223K led by PPP
Key Investors in MOgene
PPP
Public-Private Partnership
What's next for MOgene?
With the successful acquisition of this latest capital, MOgene is poised to transition into a phase of aggressive infrastructure expansion and service diversification. The strategic focus will likely center on enhancing their bioinformatics pipeline and scaling their agritech genomic capabilities to meet the rising global demand for precision agriculture. As the company navigates this late-stage growth trajectory, the emphasis will remain on maintaining the rigorous quality standards that have defined their tenure since 2004. Future initiatives are expected to prioritize the integration of emerging sequencing technologies, further cementing their role as a critical partner in the global biotech ecosystem and ensuring sustained competitive advantage in the rapidly evolving genomic services market.
See full MOgene company page
